Practical insights on deal-making covering licensing, partnering and M&A in the pharmaceutical, biotechnology, diagnostics and medical devices sector -get acquainted with state-of-the-art concepts and practices.
Introduction Getting the in-licensing discount rate wrong doesn’t just misprice a single pharmaceutical or biotech deal—it can quietly reshape a company’s entire portfolio risk profile over time. Every in-licensing decision…
Introduction Due diligence (DD) in pharmaceutical licensing and M&A has always been a resource-intensive exercise. Thousands of documents - clinical data packages, IP portfolios, regulatory submissions, commercial contracts, manufacturing records,…
Pharma Out Licensing Challenges and How to Overcome Them Out licensing in pharma and biotech is frequently described as a value-inflection event — a moment when an asset's latent potential…
Essential Strategies for Successful Out-Licensing and Partnering in Pharma and Biotech Industry Dealmaking in the pharmaceutical and biotech industries plays a pivotal role in fostering growth and innovation. Partnering and…
Key Issues Biotech and Pharma Companies Must Address to Succeed in Out-Licensing Pharma and biotech out-licensing and partnering are essential growth drivers for innovative life sciences companies. Yet, despite repeated…
How to Leverage EBITDA Multiples for Accurate Pharma Company Valuations Determining the valuation of pharmaceutical and biotechnology companies is a crucial exercise to inform high-impact decisions including organic investments and…
Mastering the Valuation of Pharma and Biotech Assets and Businesses Properly valuing drug and biotechnology assets is essential for pharmaceutical enterprises, biotech companies, investors, and other healthcare stakeholders. Valuation provides…
Introduction The pharmaceutical industry is at a critical inflection point in 2025, with research and development (R&D) continuing to grow despite global economic pressures and shifting regulatory landscapes. As thousands…
How to Navigate the Discount Rate Conundrum in Biotech and Pharma Valuation In the pharmaceutical and biotechnology industry (referred to collectively as biopharma), almost all valuation and investment decisions decisions…
Key Success Factor in Pharma Search and Evaluation and Due Diligence Licensing and partnering are critical growth strategies in the biopharma industry. The effectiveness of licensing and partnership relies heavily on…